RenalSense welcomes Giora Fishman to the team as VP Commercialization, USA. Giora is a seasoned business executive, with diverse experience in Business Development, Operations, and Sales. Prior to joining RenalSense he held senior management positions, primarily in the Healthcare Industry in the US and in Israel, with companies such as Baxter International, Bristol Myers Squibb, Datascope, and Mennen Medical.
RenalSense welcomes Michael Boxman as VP Sales & Marketing, Europe. Michael has 15 years’ experience in medical device sales and business development in the EU and has a deep understanding of the healthcare sector in the different European countries. Previously he was director of business development EMEA at Eight Medical International. Michael holds an MBA from a Dutch business school.
RenalSense has joined the Patient Safety Movement Foundation (PSMF) in making a commitment to ZERO patient harm and death, in line with our goal of reducing morbidity and mortality due to kidney injury. The PSMF is a global nonprofit organization, building a global database of organizations who are committed to eliminating preventable patient harm and death. For more information on the PSMF click here.
RenalSense welcomes Adam Goldberger as Chief Business Officer. Most recently, Adam was a Group Executive for a leading private equity-backed Australian health risk management platform company which grew exponentially utilizing a multi-brand, multi-channel approach to market. He has led entrepreneurial companies through significant growth phases and driven change management agendas through innovation and adoption of best practice.
RenalSense welcomes Yishai Klein to its Board of Directors. Yishai Klein is the Managing Partner and Co-Founder of Singapore-based venture firm, BlueRed Partners. Prior to forming BlueRed, Yishai served as both Advisor and Head of Innovation and Strategic Investments at the OUE group. Formerly, Yishai was Head of Asia at Giza Venture Capital. He currently serves on the boards of Cynet, Gauzy, DouxMatok, Optibus, Panorays and EarlySense.
RenalSense has signed a distribution agreement in Taiwan with Pacific Hospital Supply Co. (PAHSCO), an industry leader of disposable medical supplies and equipment. PAHSCO will market RenalSense’s Clarity RMS™ critical care monitoring system to hospitals throughout Taiwan.
RenalSense™ has signed a distribution agreement for mainland China with Gloryway, a leading distributor of medical devices. Gloryway will market and manufacture the Clarity RMS™ to hospitals throughout mainland China. See Press Release.
RenalSense has entered into a distribution agreement for North America with Medline, the largest privately held manufacturer and distributor of medical supplies. See Press Release.
RenalSense has signed a distribution agreement with Medtechnica, Israel’s largest distributor of medical equipment and health services. Medtechnica will market RenalSense’s Clarity RMS™ critical care monitoring system to hospitals throughout Israel. See Press Release.
RenalSense recently launched a study at Columbia University Irving Medical Center in New York under the direction of Professor Gebhard Wagener of the Department of Anesthesiology. In this study of 100 adult patients, continuous urine flow will be measured before, during, and after cardiac surgery in order to evaluate its ability to detect renal injury, assessed by the incidence of AKI and by post-operative measurements of NGAL, a urinary biomarker.
RenalSense recently released two articles in the periodical ICU Management & Practice, in a special issue dedicated to COVID-19. The first article, entitled “Continuous Monitoring of Urine Flow in COVID-19 and Other Critical Care Patients: Why and How” appeared in the online and print versions of the Journal. The second article, entitled “COVID-19 and Acute Kidney Injury” appeared in the weekly newsletter dedicated to the same topic.
Installations of the Clarity RMS are on the rise also in Israel in the COVID-19 era. The latest site, Assuta Ashdod, is a branch of Israel’s largest private chain of medical centers, where the systems are being used for patients in the general ICU, including isolated cases of COVID-19.
RenalSense has started commercial sales of its Clarity RMS™ system in Europe in conjunction with its distribution partner Fresenius Medical Care (Bad Homburg). The Clarity RMS received CE Mark approval in August 2019. See Press Release.
RenalSense has obtained CE Mark approval for its Clarity RMS™ system for real-time monitoring of urine flow in the critical care and peri-operative setting. The CE Mark approval allows the company to commercialize its technology in the European Union (EU), where Fresenius Medical Care (Bad Homburg) is its distribution partner. See Press Release.
RenalSense is one of three Israeli medtech companies that were recently awarded funding grants from the Israel Innovation Authority and the Israeli Ministry of Economy and Industry. The company received 3 million NIS for development of its second generation system.
RenalSense will be making a presentation at the “Pitch Perfect Startup Contest” at MedCity INVEST, to be held April 23-24 in Chicago. MedCity INVEST is a leading national healthcare investing conference uniting active investors with corporate business development executives to facilitate investment opportunities with the most promising healthcare startups.
As part of the 2019 AKI&CRRT meeting in San Diego, RenalSense sponsored a symposium entitled “Urine Flow Rate and its Use as a Biomarker in Critical Care.” The speakers were Professor John Kellum, Director of the Center for Critical Care Nephrology at the University of Pittsburgh, and Professor Robert Safirstein of the Department of Medicine (Nephrology) at Yale University. The presentations covered the potential of urine flow as an early indicator of AKI, and as a real-time parameter for response to therapy, and for local and systemic disease. Watch video of Kellum lecture.
In mid-December, RenalSense participated in an Israeli industry delegation to China, consisting of 26 companies selected by the China-Israel Joint Committee on Innovation Cooperation. As a member of the delegation, we conducted a speaking tour in Changzhou, Shenzhen, Shanghai and Beijing, to promote joint innovation and collaboration between the two countries.
RenalSense® announced today that it is conducting a pilot study with its Clarity RMS® critical care monitoring system at the University of Pittsburgh Medical Center (UPMC), under the direction of Professor John Kellum. See Press Release.
RenalSense is proud to announce that it was selected as one of five companies to represent Israel at the Xi’an International Entrepreneurship Competition for outstanding global innovation this December. The competition, sponsored by the Xi’an Municipal Government, includes startups in the fields of IT, bio-med, advanced manufacturing and new materials from Silicon Valley, Berlin, London, Brisbane, and Tel Aviv, as well as from six regions in China.
RenalSense® has entered into an agreement with Fresenius Medical Care (Bad Homburg) for distribution of its Clarity RMS critical care urine monitoring system in Europe, the Middle East, and Africa (EMEA). Fresenius Medical Care will market the company’s products in 85 EMEA countries through its acute care division. See Press Release.
RenalSense will be participating in the upcoming ASN Kidney Week 2017 Annual Meeting, to be held Oct 31st – Nov 5th in New Orleans.
The company will present a scientific poster entitled “Identification of the Oliguric Patient Using a Novel Electronic Device for Measuring Urine Output” on Thursday Nov 2nd in the 10:00 am Poster Session on AKI. The company will also be exhibiting at Booth #514, where visitors will have the opportunity to meet with members of the senior management team.
RenalSense published its first full-length article in the September issue of “Clinical Medicine Insights: Trauma and Intensive Medicine”.
The article describes the company’s recent clinical trial conducted in the ICU at Jerusalem’s Hadassah Hospital.
RenalSense installed its first Clarity RMS Urine Monitoring System in the surgical ICU at New York’s Mt. Sinai West (formerly Roosevelt Hospital), under the supervision of Professor Hassan Khouli.
RenalSense will be participating in the upcoming AKI&CRRT 2017 – The 22 nd International Conference on Advances in Critical Care Nephrology – Updates in ICU Medicine: Controversies, Challenges, and Solutions, to be held March 7th-10th in San Diego.
Dr. Mor Grinstein, Co-Founder and Chief Medical Officer, will be making an oral presentation entitled “A Novel Electronic Device for Measuring Urine Flow Rate” on Wednesday March 8 th in the 6:00 PM session on Clinical Research in AKI and NAP.
The company will also have an exhibition booth at the conference, where visitors will have the opportunity to meet with members of the senior management team.
RenalSense was selected as one of five companies to present at the JLM-Biocity Biomed Startup Pitch Evening held on December 20th in Jerusalem. JLM-Biocity is a private initiative of 900 bio entrepreneurs, professionals and businesspeople seeking to make Jerusalem a global life science innovation leader. The presentation was made to a panel of investors, VC funds, and global companies.
RenalSense’s clinical team presented a scientific poster at Kidney Week of the American Society of Nephrology (ASN) 2016 in Chicago. The poster summarized the findings of the company’s recent prospective trial with 40 ICU patients at Hadassah Hospital in Jerusalem, Israel. See the abstract.
Yishai Klein is the Managing Partner and Co-Founder of Singapore-based venture firm, BlueRed Partners. Prior to forming BlueRed, he served as both Advisor and Head of Innovation and Strategic Investments at the OUE group. Formerly, Yishai was Head of Asia at Giza Venture Capital. He currently serves on the boards of Cynet, Gauzy, DouxMatok, Optibus, Panorays and EarlySense.
Avi Kleiman, co-founder of RenalSense, is an experienced entrepreneur with extensive management, marketing and operations experience, 15 years of which have been in the renal and critical care space. As past CEO of MedDynamix, he transformed the company from a young start-up to a global medical device provider. Avi also founded Csoft International, a US software company acquired by Marconi Systems in 1999.
Milton Yisrael is Principal of a Family Office overseeing investments in the US and Israel in a variety of sectors including venture capital, capital markets & real estate. Founder and partner of Hadas Arazim Investment house (today part of Halman Aldubi Investment House), he currently serves as a Board Member, as well as in several other private companies. Milton holds an LLB degree from Bar Ilan University & is a member of the Israeli Bar since 1995.
Cuong Do leads the Global Strategy Group of Samsung’s diverse business portfolio. Previously, he was the Chief Strategy Officer for Merck, Tyco Electronics, and Lenovo. He was also a former senior partner at McKinsey & Company, where he spent 17 years and helped build the healthcare, high tech and corporate finance practices. Cuong holds an MBA from the Tuck School of Business at Dartmouth College.
Hagar Azran manages the company’s clinical trials in Israel and Europe. She has 17 years of experience in clinical research, 10 of which have been in renal disease. Hagar began her clinical career in the In-vitro Fertilization (IVF) Department at Hadassah Hospital in Jerusalem. She then continued her clinical research in the Ophthalmology surgical division at Kaplan Hospital. Hagar received her Bachelor’s degree in life sciences and her Master’s in endocrinology from the Hebrew University in Jerusalem
Aliza Goldman manages the company’s clinical trials in Israel and the US. Formerly a pediatric oncology nurse, she is a published clinical researcher with 10 years of focus on AKI. Aliza received her Bachelor’s in biology from Yeshiva Univ in NY, and her degree in nursing and Master’s in biotechnology from The Hebrew University in Jerusalem. She is also a Registered Nurse in the State of New York and is currently pursuing a PhD in bioethics at Bar-Ilan University in Israel.
Yosh Mantinband is a senior technology executive with extensive experience in all aspects of product design and lifecycle encompassing both hardware and software. Previously, he served in executive management positions at Microsoft, Kayote Networks, and Accent Software International Ltd. (NASDAQ: ACNTF). Yosh holds an MSc in Industrial Engineering and Ergonomics from North Carolina State University and a BSc in EECS from Northwestern University.
Yohanan Engelhardt joined RenalSense in 2015. Prior to joining RenalSense, he served for 18 years as CFO and VP Finance of ViryaNet, a global provider of mobile workforce management software solutions. During his tenure at ViryaNet he played a key role in building the accounting and finance functions, managing the integration of acquisitions, and supporting the company’s IPO and successful sale of the company in 2014 to a large private equity. Yohanan is a Certified Public Accountant in both the US and Israel.
Moti Barda has a wealth of experience in operations management in the electronics & medical device industry. In his previous positions as VP Operations at Mobileye (NYSE:MBLY) and MedDynamix, he established mass production infrastructure logistics in Israel and the Far East, managed supply chains, in- and outsourcing, QA, MRP/ERP development and implementation, and many other key functions. Moti holds an MBA and a BA in electrical engineering and electronics.
Joseph Kochba has vast and diverse experience developing and commercializing medical equipment and multidisciplinary systems. Previously, he served as VP R&D of SuperDimension, a company that introduced a unique lung navigation system for pulmonary cancer care, and as VP R&D for Pythagoras Solar, a company that developed unique building integrated photovoltaic windows. Joseph has also held several leading management roles at Orbotech.
Dr. Mor Grinstein, co-founder of RenalSense, is a published biochemist and experienced scientific and clinical researcher with 10 years of focus on AKI. He received his MSc from Hebrew University and the Max Planck Institute, and his PhD in Medicine from the Technion – Israel Institute of Technology, specializing in renal stem cells. Mor is currently a researcher at Harvard Medical School and Massachusetts General Hospital in Boston.
Adam Goldberger is an experienced business leader having held executive and CFO positions across the technology, health and professional services sectors. Most recently, he was a Group Executive for MedHealth, a leading private equity-backed Australian health risk management platform company which grew from $30m to over $300m utilizing a multi-brand, multi-channel approach to market. Adam has led entrepreneurial companies through significant growth phases and driven change management agendas through innovation and adoption of best practice.
Giora Fishman is a seasoned business executive, with diverse experience in Business Development, Operations, and Sales. Prior to joining RenalSense he held senior management positions, primarily in the Healthcare Industry in the US and in Israel, with companies such as Baxter International, Bristol Myers Squibb, Datascope, and Mennen Medical. Giora holds a B.Sc. in Mechanical Engineering from the Technion in Haifa, Israel
Michael Boxman has 15 years’ experience in medical device sales and business development in the EU and has a deep understanding of the healthcare sector in the different European countries. In his previous position as director of business development EMEA at Eight Medical International, he managed multiple business partners, increased the company’s footprint in new countries and initiated the development of a new patented medical technology. Michael holds an MBA from a Dutch business school.
Mr. Strafaci is an experienced sales and marketing executive with extensive knowledge in launching novel capital and value-added consumables in the hospital market. Most recently, he was an early team member and leader at Cogentix Medical, where he headed the endoscopy business unit with double-digit quarterly sales increases. The company was acquired by Laborie Medical Technologies. Mr. Strafaci is a published co-author in the Journal of Molecular Biology and holds a degree in Biological Sciences from Rutgers University in New Jersey.
Professor Khouli is the Chair of the Department of Critical Care Medicine in the Respiratory Institute at the Cleveland Clinic. Previously he was the Chief of the Critical Care Division at Mt. Sinai West and Mount Sinai St. Luke’s Hospitals in New York City, where he founded the Center for Advanced Medical Simulation (CAMS) and was the Chair of Medical Ethics for over 15 years. Prof. Khouli is on the advisory boards & committees of several regional and national organizations and societies.
Mr. Benhamou has over 25 years’ experience in sales management, product management and business development at companies including Siemens Healthineers, GE Healthcare and Intel Digital Health Group. With a deep understanding of international healthcare systems and the technology needs of various medical specialties, he has vast experience defining and implementing sales strategies. Mr. Benhamou holds an MSc in Biomedical Engineering from Aix-Marseille II University, France.
Dr. Grinstein is a published biochemist and experienced scientific and clinical researcher with 10 years of focus on AKI. He received his MSc from Hebrew University and the Max Planck Institute, and his PhD in Medicine from the Technion – Israel Institute of Technology, specializing in renal stem cells. Dr. Grinstein is currently a researcher at Harvard Medical School and Massachusetts General Hospital in Boston.
Mr. Kleiman is an experienced entrepreneur with extensive management, marketing and operations experience, 15 years of which have been in the renal and critical care space. As past CEO of MedDynamix, he transformed the company from a young start-up to a global medical device provider. Mr. Kleiman also founded Csoft International, a US software company acquired by Marconi Systems in 1999.
Mr. HaCohen is a seasoned C-level and investment professional with 25 years’ experience building and managing multi-national, multi-cultural companies. He is the Founder and a Managing Partner of Jerusalem Technology Investments (TASE: JTI), where he heads the Investments Committee and serves on the boards of several IT and Medical Device companies. Prior to founding JTI, Mr. HaCohen was the Founder, CEO and Chairman of ViryaNet (NASDAQ: VRYA).
Professor Safirstein is an internationally renowned nephrologist and 40-year industry veteran. He is Professor of Internal Medicine at Yale University, past Executive Vice Chair of the Dept. of Internal Medicine, University of Arkansas, and Asst. Editor of Kidney International. Dr. Safirstein holds senior positions at several major medical institutions in the US and at the NIH.
Dr. Caine, a board-certified general surgeon, is Director General of Herzog Hospital in Jerusalem. Prior to assuming his present position, he was a senior staff surgeon at the Hadassah University Hospital in Jerusalem; where he continues to practice as an active surgeon. Dr. Caine has served as Surgeon General of the Israeli Air force and was until recently the President of the International Academy of Aviation and Space Medicine.
